Metastatic BRAF-mutant melanoma
The BRAF V600E mutation constitutively activates BRAF kinase and MAPK/ERK signalling, promoting tumour progression. Melanoma is especially susceptible to immune checkpoint inhibition because it is highly immunogenic. Approximately 40–50% o…
1 sources - 3 claims
The BRAF V600E mutation constitutively activates BRAF kinase and MAPK/ERK signalling, promoting tumour progression. Melanoma is especially susceptible to immune checkpoint inhibition because it is highly immunogenic. Approximately 40–50% of metastatic melanomas have activating BRAF mutations.